Pliant Therapeutics Extends Stockholder Rights Agreement Expiration

The latest announcement is out from Pliant Therapeutics ( (PLRX) ).

On March 3, 2026, Pliant Therapeutics, Inc. amended its Stockholder Rights Agreement with Computershare Trust Company, N.A., extending the final expiration of the shareholder rights from March 11, 2026, to March 11, 2027, while leaving other core terms intact. The company stated the extension is designed to deter any entity from gaining control through open market share accumulation without paying a control premium or allowing sufficient time for the board to evaluate options, emphasizing that the move was not triggered by a specific takeover bid and is not meant to block board-approved transactions.

The most recent analyst rating on (PLRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.

Spark’s Take on PLRX Stock

According to Spark, TipRanks’ AI Analyst, PLRX is a Neutral.

The score is held down primarily by weak financial performance (large ongoing losses, no recent revenue, and significant cash burn implying runway/financing risk). Technicals add pressure with a clear downtrend and negative momentum indicators. Corporate events are mixed but modestly supportive due to debt settlement, while valuation provides limited support given negative earnings and no dividend data.

To see Spark’s full report on PLRX stock, click here.

More about Pliant Therapeutics

Pliant Therapeutics, Inc. is a biotechnology company focused on developing novel therapies, particularly in areas where modulating biological pathways can address serious diseases. The company operates in the biopharmaceutical sector, targeting conditions that may benefit from advanced, mechanism-based drug candidates in specialized markets.

Average Trading Volume: 1,238,866

Technical Sentiment Signal: Sell

Current Market Cap: $78.04M

Find detailed analytics on PLRX stock on TipRanks’ Stock Analysis page.